MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome

Recruiting Observational Study
Neonatal Opioid Withdrawal Syndrome Neonatal Abstinence Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
1 Day – 5 Days
Sex
Any
Study type
Observational
Participants needed
50 (estimated)
Sponsor
Milton S. Hershey Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Infants with neonatal abstinence syndrome (NAS) experience prolonged hospital stays and poor neurodevelopmental outcomes, in-part because of the lack of accurate, individualized, biologic assessments available to manage this increasingly common medical condition. The proposed study will define the molecular mechanisms that regulate the response to opioid withdrawal in the developing brain by focus…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Newborns ≥35weeks gestation with chronic in-utero opioid exposure (\>1month of gestation exposure). Maternal exposure will be determined by evaluating the medical records for maternal medication use, maternal urine toxicology and neonatal meconium toxicology results per standa…
Contacts

Rhea E Sullivan, B.S.

717-531-0003

rsullivan2@pennstatehealth.psu.edu

CONTACT